anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Regional anesthesia for total knee arthroplasty has been deemed high priority by national and international societies, and its use can serve as a measure of healthcare equity. The association between utilization of regional anesthesia for postoperative pain and (1) race and (2) hospital in patients undergoing total knee arthroplasty was estimated. The hypothesis was that Black patients would be less likely than White patients to receive regional anesthesia, and that variability in regional anesthesia would more likely be attributable to the hospital where surgery occurred than race.
METHODS: This study used Medicare fee-for-service claims for patients aged 65 yr or older who underwent primary total knee arthroplasty between January 1, 2011, and December 31, 2016. The primary outcome was administration of regional anesthesia for postoperative pain, defined as any peripheral (femoral, lumbar plexus, or other) or neuraxial (spinal or epidural) block. The primary exposure was self-reported race (Black, White, or Other). Clinical significance was defined as a relative difference of 10% in regional anesthesia administration.
RESULTS: Data from 733,406 cases across 2,507 hospitals were analyzed: 90.7% of patients were identified as White, 4.7% as Black, and 4.6% as Other. Median hospital-level prevalence of use of regional anesthesia was 51% (interquartile range, 18 to 79%). Black patients did not have a statistically different probability of receiving a regional anesthetic compared to White patients (adjusted estimates: Black, 53.3% [95% CI, 52.5 to 54.1%]; White, 52.7% [95% CI, 52.4 to 54.1%]; P = 0.132). Findings were robust to alternate specifications of the exposure and outcome. Analysis of variance revealed that 42.0% of the variation in block administration was attributable to hospital, compared to less than 0.01% to race, after adjusting for other patient-level confounders.
CONCLUSIONS: Race was not associated with administration of regional anesthesia in Medicare patients undergoing primary total knee arthroplasty. Variation in the use of regional anesthesia was primarily associated with the hospital where surgery occurred.
OBJECTIVES: I. Determine modulation by fenretinide of surrogate endpoint markers of oral mucosal carcinogenesis in patients with oral dysplastic leukoplakia. II. Determine whether fenretinide will cause significant modulation of intermediate endpoint markers and significant regression of oral dysplastic leukoplakia in this patient population. III. Compare the ability of fenretinide and placebo to modulate surrogate endpoint biomarkers in this patient population. IV. Document the degree of recurrence of oral dysplastic leukoplakia after the administration of fenretinide, both at the same site and at new sites.

OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to 1 of 2 treatment arms: Arm I: Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Arm II: Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.
The present invention relates to a method for manufacturing a composition of peptide, calcium and magnesium. Primarily, collagen peptide is added into soluble calcium and magnesium to resupply the lost calcium and magnesium in a human body. First, egg shells can be heated to turn into active calcium dispersed into water. The egg-shell dispersed liquid can be further added with bittern and a solution of NaOH to produce deposition of calcium hydroxide and Magnesium hydroxide, which will become dried solid calcium hydroxide after dehydration and drying. Then, the soild calcium hydroxide is dispersed into water again and added with acetic acid solution to become a solution of soluble calcium magnesium acetate. In addition, a peptide solution can be made by dispersion of fish scales in water, and then the calcium magnesium acetate solution can be added into the peptide solution to become peptide calcium magnesium solution after being heated for disinfection and filtered. At last, the peptide calcium magnesium solution can be concentrated and dried as peptide calcium magnesium. Accordingly, it can show a preventive function prominently in a human body and utilizes the antagonistic effect of calcium and magnesium to promote the uptake rate of calcium and restrain a surfeit of calcium from entering into a cell to produce side effects.
Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest. The exfoliated prostatic epithelial cells are subsequently utilized for purposes such as detecting prostate cancer, predicting/measuring prostate tumor susceptibility to drug regimes, active surveillance of patients whose prostate biopsy results are negative, but continue to exhibit symptoms consistent with prostate cancer, and identifying false positive results associated with biomarker assays.
The investigators recently developed a mutant form of rhIL-11 with improved stability. In in vitro experimental systems, mIL-11 was shown to endure chemical and proteolytic stresses more effectively, while retaining the biological activity of the original rhIL-11. The improved stability of mIL-11 was also demonstrated in the comparative pharmacokinetic study of subcutaneously delivered mIL-11 and rhIL-11 in the rodent and primate models. Based on its improved pharmacokinetic and pharmacodynamic features. In Phase II study shows that mIL-11 is well tolerated and has thrombopoietic activity equivalent to one third of the clinical dose of rhIL-11, indicating the potential of mIL-11 for use in the treatment of CIT. This study is a phase III, single-blinded, randomized,multicenter,cross-over study designed to evaluate optimal dosing dose and efficacy and safety of mIL-11 on CIT patients receiving suitable chemotherapeutic regimen for treating cancer.
All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
PURPOSE:To obtain a complex nutritional transfusion solution, composed of two solutions of a solution containing an amino acid and fats and a solution containing a saccharide and an electrolyte and stable for a long period. CONSTITUTION:This complex nutritional transfusion solution is obtained by mixing two solutions of a solution containing an amino acid and fats (e.g. L- isoleucine-soybean oil) and a solution containing a saccharide and an electrolyte (e.g. glucose-potassium chloride) in use. The fat concentration in the solution containing the amino acid and the fats is preferably 2-10wt.% expressed in terms of the whole amino acid and 0.5-3 pts.wt. fats is mixed with 1 pt.wt. amino acid. The saccharide concentration in the solution containing the saccharide and the electrolyte is preferably 15-60wt.%. The transfusion solution is filled in a flexible plastic bag, a rigid plastic bottle, etc. Since this solution can stably be preserved for a long period and complicated operation is not required in administering to a patient, it can be administered without causing pollution due to microorganisms and fine particles.
OBJECTIVES: The new corona virus infection, has a wide range of clinical manifestations. Fever and cough are the most common symptoms. The olfactory function may be also affected with COVID-19. In this randomized clinical trial, we wanted to evaluate the therapeutic effect of olfactory training with and without oral vitamin A for COVID-19-related olfactory dysfunction.
METHODS: Patients answered to the standard Persian version of anosmia reporting tool and performed the quick smell test before and after 12 weeks and at the end of the 12 months follow up. The patients were randomly allocated to three groups; Group A treatment with olfactory training, Group B treatment with oral vitamin A and olfactory training, and Group C as control group which only underwent nasal irrigation twice a day. Patients were treated for 3 months and followed up for 12 months.
RESULTS: Totally 90 patients were included in three groups. After interventions, 76.9% of patients in Group A, 86.7% of patients in Group B, and 26.7% of patients in Group C completely improved. The average intervention time was statistically significant in relationship with the final olfactory status of the patients in the 12 months follow-up. The olfactory training has significantly improved the smell alteration at the end of 3- and 12- months follow-up in A and B groups.
CONCLUSION: A three-months olfactory training is effective for improvement of COVID-19-related olfactory dysfunction. Adding daily oral vitamin A to olfactory training did not lead to better results in improving olfactory dysfunction.
LEVEL OF EVIDENCE: Step 2 (Level 2*): Randomized trial.
The invention provides an oral medicine for remedying stomachache. The medicine is made from the raw materials with the following portions of 5-12 portions of magnolia officinalis, 4-6 portions of tangerine peel, 4-6 portions of immature tangerine, 4-6 portions of cyperus rotundus l, 4-6 portions of citrus aurantium, 4-6 portions of Szechwan lovage rhizome, 4-6 portions of rhizoma corydalis, 4-6 portions of turmeric, 1-8 portions of cortex moutan, 4-6 portions of white peony root, 4-6 portions of amomum, 1-7 portions of angelica, 4-9 portions of evodia rutaecarpa, 1-8 portions of cardamom, 1-7 portions of clove, 1-7 portions of eaglewood, 1-7 portions of cinnamon, 4-6 portions of , 1-7 portions of rosa banksiae, 1-7 portions of poria cocos, 4-6 portions of sodium bicarbonate and 4-6 portions of prepared licorice. The clinic of the oral medicine is mainly used for remedying acute or chronic gastritis, gastric ulcer, chronic atrophic gastritis, dyspepsia, chronic hepatitis b and so on. The total effective rate for remedying chronic gastritis is 94.7 percent. The total effective rate for remedying gastric ulcer and chronic atrophic gastritis is 93.9 percent. The total effective rate for remedying dyspepsia is 96.1 percent, and at the same time, the oral medicine also has efficacy for remedying chronic hepatitis B.
PURPOSE:The titled remedy, containing a 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof and excellent in aspects of safety and side effect. CONSTITUTION:A remedy for hepatopathy obtained by containing 2-phenyl-1,2- benzisoselenazol-3(2H)-one or a salt thereof as an active ingredient. The dose thereof is 100-600mg/adult/day for oral administration and 30-120mg/adult/day for parenteral administration. Examples of the dosage form include capsule, tablet, powder, syrup, ampule, etc. The use thereof together with other agents can be carried out to produce additional and synergistic effect thereby. The remedy has improving effect on hepatic necrocytosis, hepatic dysfunction and lipid peroxidation and is effective in preventing and treating human acute or chronic hepatitis, fatty liver and hepatocirrhosis.
A formulation comprising an oligonucleotide selected from the group consisting of an oligonucleotide having one of SEQ ID No.:1 through SEQ ID No.:42 or a variant thereof. Also, a method of treating anesthesia-induced neurotoxicity. The method may comprise administering the formulation. The formulation may be administered prior to, concomitant with, subsequent to, or combinations thereof administration of a general anesthetic comprising a fluorinated compound. The oligonucleotide may be incorporated into a carrier system, for example, a liposome, a biodegradable polymer, a hydrogel, or a cyclodextrin, a nucleic acid complex, a virosome, or combinations thereof. Also, a method of treating anesthesia-induced neurotoxicity.
Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
Inherited retinal diseases (IRDs) are a group of rare monogenic diseases with high genetic heterogeneity (pathogenic variants identified in over 280 causative genes). The genetic diagnostic rate for IRDs is around 60%, mainly thanks to the routine application of next-generation sequencing (NGS) approaches such as extensive gene panels or whole exome analyses. Whole-genome sequencing (WGS) has been reported to improve this diagnostic rate by revealing elusive variants, such as structural variants (SVs) and deep intronic variants (DIVs). We performed WGS on 33 unsolved cases with suspected autosomal recessive IRD, aiming to identify causative genetic variants in non-coding regions or to detect SVs that were unexplored in the initial screening. Most of the selected cases (30 of 33, 90.9%) carried monoallelic pathogenic variants in genes associated with their clinical presentation, hence we first analyzed the non-coding regions of these candidate genes. Whenever additional pathogenic variants were not identified with this approach, we extended the search for SVs and DIVs to all IRD-associated genes. Overall, we identified the missing causative variants in 11 patients (11 of 33, 33.3%). These included three DIVs in ABCA4, CEP290 and RPGRIP1; one non-canonical splice site (NCSS) variant in PROM1 and three SVs (large deletions) in EYS, PCDH15 and USH2A. For the previously unreported DIV in CEP290 and for the NCCS variant in PROM1, we confirmed the effect on splicing by reverse transcription (RT)-PCR on patient-derived RNA. This study demonstrates the power and clinical utility of WGS as an all-in-one test to identify disease-causing variants missed by standard NGS diagnostic methodologies.
PURPOSE: Recent observational studies have indicated the efficacy of stent retriever devices for the treatment of posthemorrhagic cerebral vasospasm (CVS), both by deployment and on-site withdrawal into the microcatheter (stent angioplasty, SA) and deployment followed by retraction through the target vessel similar to thrombectomy (Stent Retraction to reLieve Arterial Cerebral vaSospasm caused by SAH, Stent-ReLACSS). This article reports the findings with each application of pRESET and pRELAX in the treatment of CVS.
METHODS: We retrospectively enrolled 25 patients with severe CVS following aneurysmal subarachnoid hemorrhage. For the SA group, a stent retriever or a pRELAX was temporarily deployed into a narrow vessel segment and retrieved into the microcatheter after 3 min. For the Stent-ReLACSS group, a pRELAX was temporarily deployed into a narrow vessel and pulled back unfolded into the internal carotid artery. If intra-arterial vasodilators were administered, they were given exclusively after mechanical vasospasmolysis to maximize the effectiveness of the stent treatment.
RESULTS: In this study fifteen patients and 49 vessels were treated with SA. All were technically successful without periprocedural complications; however, 8/15 patients (53.3%) required additional treatment of the CVS. A total of 10 patients and 23 vessel segments were treated with Stent-ReLACSS. All maneuvers were technically successful without periprocedural complications and all vessels showed significant angiographic improvement. No recurrent CVS requiring further endovascular treatment occurred in-hospital, and neither territorial ischemia in the treated vessels nor vascular injury were observed in follow-up angiography.
CONCLUSION: Based on the presented data it appears that Stent-ReLACSS with pRELAX does not pose any additional risks when used to treat CVS and might be superior to SA, especially concerning mid-term and long-term efficacy. The mechanism of action may be an effect on the endothelium rather than mechanical vasodilation. As many patients with CVS are diagnosed too late, prophylactic treatment of high-risk patients (e.g., poor grade, young, female) is potentially viable.
Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
PURPOSE OF REVIEW: The complexity of pediatric mental and behavioral health (MBH) complaints presenting to emergency departments (EDs) is increasing at an alarming rate. Children may present with agitation or develop agitation during the ED visit. This causes significant distress and may lead to injury of the child, caregivers, or medical staff. This review will focus on providing safe, patient-centered care to children with acute agitation in the ED.
RECENT FINDINGS: Approaching a child with acute agitation in the ED requires elucidation on the cause and potential triggers of agitation for optimal management. The first step in a patient-centered approach is to use the least restrictive means with behavioral and environmental strategies. Restraint use (pharmacologic or physical restraint) should be reserved where these modifications do not result in adequate de-escalation. The provider should proceed with medications first, using the child's medication history as a guide. The use of physical restraint is a last resort to assure the safety concerns of the child, family, or staff, with a goal of minimizing restraint time.
SUMMARY: Children are increasingly presenting to EDs with acute agitation. By focusing primarily on behavioral de-escalation and medication strategies, clinicians can provide safe, patient-centered care around these events.
The invention relates to an SOD skin care product and a preparation method. 10-15 parts by weight of SOD is added into an auxiliary solution to perform mixing, freezing is performed at the temperature of below -100 DEG C for 3-6 minutes, and then freeze drying is performed to enable a mixture to be in a solid state. The auxiliary solution is an aqueous solution prepared by 2-5 parts by weight of bonder, 20-30 parts of humectants and 5-10 parts by weight of trehalose. The SOD skin care product has the effect of the SOD, meanwhile the activity preservation of the SOD at normal temperature for a long period of time is also ensured, and the activity retention rate of the SOD skin care product stored at the normal temperature for two years is up to 90% after double-aluminum package sealing is performed. Existing liquid bottled skin care products are replaced. Double-aluminum package can be adopted for the SOD skin care product, and the SOD skin care product is light, small, exquisite and convenient to carry about.
The goal of this pilot study is to determine whether the efficacy of an existing lifestyle improvement program can be increased by adding a sleep extension and sleep hygiene intervention. Improved sleep can improve weight loss through two possible routes: lessening fatigue may potentiate physical activity (PA), and decreasing appetite may potentiate diet improvements. A sample of 24-30 women will be assigned to either the Centers for Disease Control's (CDC's) standard PreventT2 program or the same program with an additional integrated sleep intervention. Both programs will involve 8 group sessions administered over 3 months, and all women will be followed for a total of 6 months. The primary outcome is weight loss, and secondary outcomes include sleep quality and duration, physical activity, caloric intake, and physiological indicators of cardiovascular and diabetes risk (HbA1c, HOMA-IR, lipids, blood pressure). The combined program has the potential to significantly improve weight loss in those at risk for diabetes and cardiovascular disease (CVD).
The present invention belongs to a health care cigarette for preventing phlogosis in a nasal cavity, particularly to a health care cigarette for a nasal cavity and a making method. The present invention adopts stem leaves of mentha spicata, honey and medical dextrose powder as raw materials. The raw materials are weighed according to a weight compounding ratio. The stem leaves of mentha spicata are immersed in water and then are aired, the stem leaves of mentha spicata are cut into fine filaments, the honey is diluted, heated and boiled, the stem leaves of mentha spicata are cut into filaments, the diluted heated honey and the medical dextrose powder are thoroughly and uniformly mixed, and tobacco shreds are rolled into the cigarette by a cigarette machine. After the health care cigarette of the present invention is lit and smoked, smoke gas passes through a nasal cavity, which plays the health care function for the nasal cavity of a person and prevents phlogosis in the nasal cavity. The present invention has the functions of ventilation and refection. The present invention has no toxic effect or side effect for a human body. The use is convenient.
Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
Ophthalmologic toxicity has occurred in patients receiving interferon alfa products, including BESREMi. These toxicities may include severe eye disorders such as retinopathy, retinal hemorrhage, retinal exudates, retinal detachment and retinal artery or vein occlusion which may result in blindness. During BESREMi therapy, 23% of patients were identified with an eye disorder. Eyes disorders ≥5% included cataract (6%) and dry eye (5%). Advise patients to have eye examinations before and during BESREMi therapy, specifically in those patients with a retinopathy-associated disease such as diabetes mellitus or hypertension. Evaluate eye symptoms promptly. Discontinue BESREMi in patients who develop new or worsening eye disorders.
7669. Henri, V., Helbronner, A., and Recklinghausen, M. von. March 29. Toxines, anti - toxines, and like bacterial products; bacteria, cultivating. - Tuberculin, or tuberculous bacilli which may be used for obtaining medical serums, are obtained in an attenuated condition by treatment with ultra-violet rays. The liquid to be treated is placed in a quartz-tube 1 adapted to be rotated so as to expose a thin film of the liquid to the action of a mercury-vapour lamp 10. Fig. 2 shows a modification in which the liquid is passed through a zigzag tube 12.